Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Secondary organising pneumonia associated to COVID-19 infection in patients with central nervous system inflammatory demyelinating diseases treated with anti-CD20 therapies.
Carvajal R, Rodríguez-Acevedo B, García-Vasco L, Zabalza A, Ariño H, Bollo L, Cabello-Clotet N, Castilló J, Cobo-Calvo Á, Comabella M, Falcó-Roget A, Galán I, García-Sarreón A, Gómez-Estévez I, Granados G, La Puma D, Mato Chain G, Midaglia L, Nieto-García A, Otero-Romero S, Pappolla A, Rodriguez M, Sansano I, Río J, Tagliani P, Tur C, Vidal-Jordana Á, Vilaseca A, Villar A, Sastre-Garriga J, Oreja-Guevara C, Tintoré M, Montalban X, Arrambide G. Carvajal R, et al. Among authors: pappolla a. Mult Scler. 2024 Nov 9:13524585241297038. doi: 10.1177/13524585241297038. Online ahead of print. Mult Scler. 2024. PMID: 39520297
MiRNA-based therapeutic potential in multiple sclerosis.
Zabalza A, Pappolla A, Comabella M, Montalban X, Malhotra S. Zabalza A, et al. Among authors: pappolla a. Front Immunol. 2024 Aug 29;15:1441733. doi: 10.3389/fimmu.2024.1441733. eCollection 2024. Front Immunol. 2024. PMID: 39267760 Free PMC article. Review.
Selection of disease modifying therapies in multiple sclerosis based on patient's age and disease activity: Data from a nationwide registry.
Piedrabuena MA, Correale J, Fiol M, Marrodan M, Rojas JI, Alonso M, Pappolla A, Miguez J, Patrucco L, Cristiano E, Vrech C, Cohen L, Alonso R, Silva B, Luetic G, Deri N, Burgos M, Liwacki S, Piedrabuena R, Tkachuk V, Barboza A, Martinez A, Balbuena ME, Pinheiro AA, Nofal P, Lopez PA, Tavolini D, Leguizamon F, Hryb JP, Tizio S, Recchia L, Reich E, Contentti EC, Marcilla MP, Pagani F, Cabrera LM, Curbelo MC, Mainella C, Liguori NF, Coppola M, Pettinicchi JP, Carra A, Jose G, Nadur D, Bestoso S, Pestchanker C, Vazquez GD, Martinez CM, Ysrraelit MC. Piedrabuena MA, et al. Among authors: pappolla a. J Neurol Sci. 2024 Jun 15;461:123052. doi: 10.1016/j.jns.2024.123052. Epub 2024 May 16. J Neurol Sci. 2024. PMID: 38797140
Vaccine Safety and Immunogenicity in Patients With Multiple Sclerosis Treated With Natalizumab.
Carvajal R, Zabalza A, Carbonell-Mirabent P, Martínez-Gómez X, Esperalba J, Pappolla A, Rando A, Cobo-Calvo A, Tur C, Rodriguez M, Río J, Comabella M, Castilló J, Rodrigo-Pendás JÁ, Braga N, Mongay-Ochoa N, Guío-Sánchez C, Vidal-Jordana Á, Arrambide G, Rodríguez-Acevedo B, Midaglia L, Borras-Bermejo B, Galán I, Sastre-Garriga J, Montalban X, Otero-Romero S, Tintoré M. Carvajal R, et al. Among authors: pappolla a. JAMA Netw Open. 2024 Apr 1;7(4):e246345. doi: 10.1001/jamanetworkopen.2024.6345. JAMA Netw Open. 2024. PMID: 38607624 Free PMC article.
Clusterin deficiency is associated with a lack of response to teriflunomide in multiple sclerosis.
Malhotra S, Fissolo N, Rodríguez-Rivera C, Monreal E, Montpeyo M, Urcelay E, Triviño JC, Pérez-García MJ, Segura MF, Pappolla A, Río J, Vilaseca A, Fernández Velasco JI, Miguez A, Goicoechea C, Martinez-Vicente M, Villar LM, Montalban X, Comabella M. Malhotra S, et al. Among authors: pappolla a. Clin Transl Med. 2024 Apr;14(4):e1654. doi: 10.1002/ctm2.1654. Clin Transl Med. 2024. PMID: 38591764 Free PMC article. No abstract available.
Prediction of disease activity and treatment failure in relapsing-remitting MS patients initiating daily oral DMTs.
Pappolla A, Auger C, Sao-Aviles A, Tur C, Rodriguez-Barranco M, Cobo-Calvo Á, Mongay-Ochoa N, Rodríguez-Acevedo B, Zabalza A, Midaglia L, Carbonell-Mirabent P, Carvajal R, Castilló-Justribó J, Braga N, Bollo L, Vidal-Jordana A, Arrambide G, Nos C, Salerno A, Galán I, Comabella M, Sastre-Garriga J, Tintoré M, Rovira A, Montalban X, Río J. Pappolla A, et al. Mult Scler. 2024 Jun;30(7):820-832. doi: 10.1177/13524585241240653. Epub 2024 Mar 29. Mult Scler. 2024. PMID: 38551315
Trans-Synaptic Degeneration in the Visual Pathway in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
Bollo L, Arrambide G, Cobo-Calvo A, Alvarez JV, Alberich M, Cabello S, Castilló J, Galan I, Midaglia LS, Acevedo BR, Zabalza A, Pappolla A, Mongay Ochoa N, Tintore M, Rio J, Comabella M, Tur C, Auger C, Sastre-Garriga J, Rovira A, Montalban X, Pareto D, Vidal-Jordana A. Bollo L, et al. Among authors: pappolla a. Neurology. 2024 Apr 9;102(7):e209156. doi: 10.1212/WNL.0000000000209156. Epub 2024 Mar 6. Neurology. 2024. PMID: 38447105
Incidence of SARS-CoV-2 infection in patients with multiple sclerosis who received SARS-CoV-2 vaccines and are under treatment with high-efficacy therapies in Argentina.
Carnero Contentti E, López PA, Pappolla A, Alonso R, Silva B, Deri N, Balbuena ME, Burgos M, Luetic G, Alvez Pinheiro A, Cabrera M, Hryb J, Nofal P, Pestchanker C, Vrech C, Tavolini D, Tkachuk V, Zanga G, Marrodan M, Ysrraelit MC, Correale J, Carrá A, Federico B, Garcea O, Fernandez Liguori N, Patrucco L, Cristiano E, Giunta D, Alonso Serena M, Rojas JI; on behalf RelevarEM. Carnero Contentti E, et al. Among authors: pappolla a. Neurol Sci. 2024 Feb;45(2):379-389. doi: 10.1007/s10072-023-07282-x. Epub 2023 Dec 30. Neurol Sci. 2024. PMID: 38159147
Mortality of neuromyelitis optica spectrum disorder patients in an Argentinean population: A study from the RelevarEM registry.
Carnero Contentti E, Lopez PA, Pettinicchi JP, Criniti J, Pappolla A, Miguez J, Cristiano E, Patrucco L, Liwacki S, Tkachuk V, Balbuena ME, Vrech C, Deri N, Correale J, Marrodan M, Ysrraelit MC, Leguizamon F, Luetic G, Menichini ML, Tavolini D, Mainella C, Zanga G, Burgos M, Hryb J, Barboza A, Lazaro L, Alonso R, Fernández Liguori N, Nadur D, Alonso Serena M, Caride A, Paul F, Rojas JI. Carnero Contentti E, et al. Among authors: pappolla a. Mult Scler J Exp Transl Clin. 2023 Oct 17;9(4):20552173231205444. doi: 10.1177/20552173231205444. eCollection 2023 Oct-Dec. Mult Scler J Exp Transl Clin. 2023. PMID: 37854639 Free PMC article.
A single-dose strategy for immunization with live attenuated vaccines is an effective option before treatment initiation in multiple sclerosis patients.
Carvajal R, Tur C, Martínez-Gómez X, Bollo L, Esperalba J, Rodriguez M, Pappolla A, Cobo-Calvo A, Carbonell P, Borras-Bemejo B, Río J, Castilló J, Braga N, Mongay-Ochoa N, Rodrigo-Pendás JÁ, Vidal-Jordana Á, Arrambide G, Rodríguez-Acevedo B, Zabalza A, Midaglia L, Galán I, Comabella M, Sastre-Garriga J, Montalban X, Tintoré M, Otero-Romero S. Carvajal R, et al. Among authors: pappolla a. Mult Scler. 2023 Dec;29(14):1841-1848. doi: 10.1177/13524585231200303. Epub 2023 Sep 20. Mult Scler. 2023. PMID: 37728389 Free PMC article.
59 results